shutterstock_1425740486_ii_studio
II Studio / Shutterstock.com
24 July 2019AmericasRory O'Neill

Gilead licenses HIV injections for $25m

Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 May 2026   Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.
Americas
26 May 2026   Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.
Americas
22 May 2026   A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.